NASDAQ:ETNB 89BIO Q4 2023 Earnings Report $8.61 -0.63 (-6.82%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$9.05 +0.44 (+5.10%) As of 09/4/2025 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast 89BIO EPS ResultsActual EPS-$0.50Consensus EPS -$0.49Beat/MissMissed by -$0.01One Year Ago EPSN/A89BIO Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/A89BIO Announcement DetailsQuarterQ4 2023Date2/29/2024TimeAfter Market ClosesConference Call DateThursday, February 29, 2024Conference Call Time4:00PM ETUpcoming Earnings89BIO's Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled on Friday, November 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) 89BIO Earnings Headlines89bio assumed with a Buy at H.C. WainwrightSeptember 4 at 7:12 PM | msn.com89bio, Inc. (ETNB) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 3 at 4:06 PM | seekingalpha.comBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated billions of shares. Bill Gates sold 500,000 shares of Microsoft. Jeff Bezos filed to sell Amazon shares worth $4.8 billion. What is going on? One multi-millionaire believes they are preparing for a catastrophic event. But not a crash, bank run, or recession. It’s something we haven’t see in America for more than a century. | Banyan Hill Publishing (Ad)89BIO (NASDAQ:ETNB) Given "Sell (D-)" Rating at Weiss RatingsAugust 31, 2025 | americanbankingnews.com89bio to Participate in Upcoming Investor ConferencesAugust 28, 2025 | globenewswire.com89bio price target lowered to $29 from $30 at BofAAugust 25, 2025 | msn.comSee More 89BIO Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like 89BIO? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 89BIO and other key companies, straight to your email. Email Address About 89BIO89BIO (NASDAQ:ETNB), Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for metabolic and endocrine disorders. The company’s lead investigational asset, BIO89-100 (pegozafermin), is a long-acting analog of fibroblast growth factor 21 (FGF21) designed to address underlying drivers of nonalcoholic steatohepatitis (NASH), severe hypertriglyceridemia and related metabolic diseases. By leveraging protein engineering and proprietary delivery technologies, 89bio aims to improve metabolic health through targeted modulation of lipid and glucose pathways. In addition to its NASH program, 89bio is exploring indications that include glycogen storage disease and other rare metabolic conditions with high unmet medical need. The company has advanced BIO89-100 into multiple clinical trials across North America and Europe, generating safety and efficacy data to support potential regulatory filings. Its research and development efforts are complemented by collaborations with academic centers and contract research organizations to accelerate patient enrollment and expand the understanding of FGF21 biology. Headquartered in Redwood City, California, 89bio was founded in 2018 and completed its initial public offering on the NASDAQ under the ticker ETNB in 2022. Under the leadership of Chief Executive Officer Arndt Zhang, the company is building a pipeline of endocrine therapies aimed at transforming the treatment landscape for patients with chronic metabolic diseases.Written by Jeffrey Neal JohnsonView 89BIO ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Affirm Crushes Earnings Expectations, Turns Bears into BelieversAmbarella's Earnings Prove Its Edge AI Strategy Is a WinnerWhat to Watch for From D-Wave Now That Earnings Are DoneDICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 Outlook Upcoming Earnings Synopsys (9/9/2025)Oracle (9/9/2025)Adobe (9/11/2025)FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
